The number of intestinal bacteria is not critical for the enhancement of antitumor activity and reduction of intestinal toxicity of irinotecan by the Chinese herbal medicine PHY906 (KD018)

BMC Complementary and Alternative Medicine

Volumn 14, Issue 1, 2014, Pages

  Lam, Wing ^a   Jiang, Zaoli ^a   Guan, Fulan ^a   Hu, Rong ^a   Liu, Shwu Huey ^a   Chu, Edward ^b   Cheng, Yung Chi ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; DNA 16S; GRANULOCYTE COLONY STIMULATING FACTOR; HERBACEOUS AGENT; INTERLEUKIN 6; IRINOTECAN; LGR5 PROTEIN; MONOCYTE CHEMOTACTIC PROTEIN 1; NEOMYCIN; OLFM4 PROTEIN; PHY 906; PROTEIN; STREPTOMYCIN; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; ANTIINFECTIVE AGENT; CAMPTOTHECIN; G PROTEIN COUPLED RECEPTOR; LGR5 PROTEIN, HUMAN; MESSENGER RNA; OLFM4 PROTEIN, HUMAN; TUMOR NECROSIS FACTOR; CELL PROTEIN; CHINESE DRUG; CYCLINE;

ANIMAL CELL; ANTIBIOTIC THERAPY; ANTIINFLAMMATORY ACTIVITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; BACTEROIDES; CANCER CELL; CANCER GROWTH; CHINESE MEDICINE; CLOSTRIDIUM COCCOIDES; CLOSTRIDIUM LEPTUM; COLON CANCER; CONTROLLED STUDY; CRYPT CELL; ENTERITIS; ENTEROCOCCUS; EUBACTERIUM RECTALE; FEMALE; GASTROINTESTINAL TOXICITY; GENE EXPRESSION; HERBAL MEDICINE; IN VIVO STUDY; INTESTINE FLORA; INTESTINE INJURY; JEJUNUM; LACTOBACILLUS; MOUSE; NEUTROPHIL; NEUTROPHIL CHEMOTAXIS; NONHUMAN; STAINING; WEIGHT REDUCTION; ANALOGS AND DERIVATIVES; ANIMAL; BACTERIUM; COLONIC NEOPLASMS; DRUG EFFECTS; GENETICS; GROWTH, DEVELOPMENT AND AGING; HUMAN; INTESTINE; METABOLISM; MICROBIOLOGY; PATHOLOGY; PHYTOTHERAPY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; BACTERIAL COUNT; CLOSTRIDIUM; DRUG POTENTIATION; EUBACTERIUM; IMMUNOHISTOCHEMISTRY; INTESTINAL STEM CELL; POLYMERASE CHAIN REACTION; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS;

ANIMALS; ANTI-BACTERIAL AGENTS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; BACTERIA; CAMPTOTHECIN; COLONIC NEOPLASMS; DRUGS, CHINESE HERBAL; FEMALE; GRANULOCYTE COLONY-STIMULATING FACTOR; HUMANS; INTESTINES; MICE; NEUTROPHIL INFILTRATION; PHYTOTHERAPY; RECEPTORS, G-PROTEIN-COUPLED; RNA, MESSENGER; TUMOR NECROSIS FACTOR-ALPHA; WEIGHT LOSS;

EID: 84928735024     PISSN: None     EISSN: 14726882     Source Type: Journal    
DOI: 10.1186/1472-6882-14-490.     Document Type: Article

References (57)

1. Tilton R, Paiva AA, Guan JQ, Marathe R, Jiang Z, van Eyndhoven W, Bjoraker J, Prusoff Z, Wang H, Liu SH, Cheng YC: A comprehensive platform for quality control of botanical drugs (PhytomicsQC): a case study of Huangqin Tang (HQT) and PHY906. Chin Med 2010, 5:30.10.1186/1749-8546-5-30.
2. Khanna R, Morton CL, Danks MK, Potter PM: Proficient metabolism of irinotecan by a human intestinal carboxylesterase. Cancer Res 2000,60(17):4725-4728.
3. Morton CL, Wierdl M, Oliver L, Ma MK, Danks MK, Stewart CF, Eiseman JL, Potter PM: Activation of CPT-11 in mice: identification and analysis of a highly effective plasma esterase. Cancer Res 2000,60(15):4206-4210.
4. Satoh T, Hosokawa M, Atsumi R, Suzuki W, Hakusui H, Nagai E: Metabolic activation of CPT-11, 7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxycamptothecin, a novel antitumor agent, by carboxylesterase. Biol Pharm Bull 1994,17(5):662-664.10.1248/bpb.17.662.
5. Ikuno N, Soda H, Watanabe M, Oka M: Irinotecan (CPT-11) and characteristic mucosal changes in the mouse ileum and cecum. J Natl Cancer Inst 1995,87(24):1876-1883.10.1093/jnci/87.24.1876.
6. Rivory LP, Bowles MR, Robert J, Pond SM: Conversion of irinotecan (CPT-11) to its active metabolite, 7-ethyl-10-hydroxycamptothecin (SN-38), by human liver carboxylesterase. Biochem Pharmacol 1996,52(7):1103-1111.10.1016/0006-2952(96)00457-1.
7. Humerickhouse R, Lohrbach K, Li L, Bosron WF, Dolan ME: Characterization of CPT-11 hydrolysis by human liver carboxylesterase isoforms hCE-1 and hCE-2. Cancer Res 2000,60(5):1189-1192.
8. Takimoto CH, Morrison G, Harold N, Quinn M, Monahan BP, Band RA, Cottrell J, Guemei A, Llorens V, Hehman H, Ismail AS, Flemming D, Gosky DM, Hirota H, Berger SJ, Berger NA, Chen AP, Shapiro JD, Arbuck SG, Wright J, Hamilton JM, Allegra CJ, Grem JL: Phase I and pharmacologic study of irinotecan administered as a 96-hour infusion weekly to adult cancer patients. J Clin Oncol 2000,18(3):659-667.
9. Herben VM, Schellens JH, Swart M, Gruia G, Vernillet L, Beijnen JH, ten Bokkel Huinink WW: Phase I and pharmacokinetic study of irinotecan administered as a low-dose, continuous intravenous infusion over 14 days in patients with malignant solid tumors. J Clin Oncol 1999,17(6):1897-1905.
10. Valenti Moreno V, Brunet Vidal J, Manzano Alemany H, Salud Salvia A, Llobera Serentill M, Cabezas Montero I, Servitja Tormo S, Sopena Bert E, Guma Padro J: Prevention of irinotecan associated diarrhea by intestinal alkalization. A pilot study in gastrointestinal cancer patients. Clin Transl Oncol 2006,8(3):208-212.10.1007/s12094-006-0012-1.
11. Tamura T, Yasutake K, Nishisaki H, Nakashima T, Horita K, Hirohata S, Ishii A, Hamano K, Aoyama N, Shirasaka D, Kamigaki T, Kasuga M: Prevention of irinotecan-induced diarrhea by oral sodium bicarbonate and influence on pharmacokinetics. Oncology 2004,67(5-6):327-337.
12. Benson AB 3rd, Ajani JA, Catalano RB, Engelking C, Kornblau SM, Martenson JA Jr, McCallum R, Mitchell EP, O'Dorisio TM, Vokes EE, Wadler S: Recommended guidelines for the treatment of cancer treatment-induced diarrhea. J Clin Oncol 2004,22(14):2918-2926.10.1200/JCO.2004.04.132.
13. Rosenoff SH: Octreotide LAR resolves severe chemotherapy-induced diarrhoea (CID) and allows continuation of full-dose therapy. Eur J Cancer Care (Engl) 2004,13(4):380-383.10.1111/j.1365-2354.2004.00511.x.
14. Ychou M, Douillard JY, Rougier P, Adenis A, Mousseau M, Dufour P, Wendling JL, Burki F, Mignard D, Marty M: Randomized comparison of prophylactic antidiarrheal treatment versus no prophylactic antidiarrheal treatment in patients receiving CPT-11 (irinotecan) for advanced 5-FU-resistant colorectal cancer: an open-label multicenter phase II study. Am J Clin Oncol 2000,23(2):143-148.10.1097/00000421-200004000-00008.
15. Karthaus M, Ballo H, Abenhardt W, Steinmetz T, Geer T, Schimke J, Braumann D, Behrens R, Behringer D, Kindler M, Messmann H, Boeck HP, Greinwald R, Kleeberg U: Prospective, double-blind, placebo-controlled, multicenter, randomized phase III study with orally administered budesonide for prevention of irinotecan (CPT-11)-induced diarrhea in patients with advanced colorectal cancer. Oncology 2005,68(4-6):326-332.
16. Duffour J, Gourgou S, Seitz JF, Senesse P, Boutet O, Castera D, Kramar A, Ychou M: Efficacy of prophylactic anti-diarrhoeal treatment in patients receiving Campto for advanced colorectal cancer. Anticancer Res 2002,22(6B):3727-3731.
17. Evaluation of Genomic Applications in P, Prevention Working G: Recommendations from the EGAPP Working Group: can UGT1A1 genotyping reduce morbidity and mortality in patients with metastatic colorectal cancer treated with irinotecan? Genet Med 2009,11(1):15-20.
18. Vasudev NS, Jagdev S, Anthoney DA, Seymour MT: Intravenous irinotecan plus oral ciclosporin. Clin Oncol 2005,17(8):646-649.10.1016/j.clon.2005.06.009.
19. Desai AA, Kindler HL, Taber D, Agamah E, Mani S, Wade-Oliver K, Ratain MJ, Vokes EE: Modulation of irinotecan with cyclosporine: a phase II trial in advanced colorectal cancer. Cancer Chemother Pharmacol 2005,56(4):421-426.10.1007/s00280-005-1020-5.
20. Fakih MG, Rustum YM: Does celecoxib have a role in the treatment of patients with colorectal cancer? Clin Colorectal Cancer 2009,8(1):11-14.10.3816/CCC.2009.n.002.
21. Sakata Y, Suzuki H, Kamataki T: Preventive effect of TJ-14, a kampo (Chinese herb) medicine, on diarrhea induced by irinotecan hydrochloride (CPT-11). Gan to kagaku ryoho Cancer Chemother 1994,21(8):1241-1244.
22. Mori K, Kondo T, Kamiyama Y, Kano Y, Tominaga K: Preventive effect of Kampo medicine (Hangeshashin-to) against irinotecan-induced diarrhea in advanced non-small-cell lung cancer. Cancer Chemother Pharmacol 2003,51(5):403-406.
23. Tobin PJ, Beale P, Noney L, Liddell S, Rivory LP, Clarke S: A pilot study on the safety of combining chrysin, a non-absorbable inducer of UGT1A1, and irinotecan (CPT-11) to treat metastatic colorectal cancer. Cancer Chemother Pharmacol 2006,57(3):309-316.10.1007/s00280-005-0053-0.
24. Kehrer DF, Sparreboom A, Verweij J, de Bruijn P, Nierop CA, van de Schraaf J, Ruijgrok EJ, de Jonge MJ: Modulation of irinotecan-induced diarrhea by cotreatment with neomycin in cancer patients. Clin Cancer Res 2001,7(5):1136-1141.
25. Alimonti A, Satta F, Pavese I, Burattini E, Zoffoli V, Vecchione A: Prevention of irinotecan plus 5-fluorouracil/leucovorin-induced diarrhoea by oral administration of neomycin plus bacitracin in first-line treatment of advanced colorectal cancer. Ann Oncol 2003,14(5):805-806.10.1093/annonc/mdg192.
26. de Jong FA, Kehrer DF, Mathijssen RH, Creemers GJ, de Bruijn P, van Schaik RH, Planting AS, van der Gaast A, Eskens FA, Janssen JT, Ruit JB, Verweij J, Sparreboom A, de Jonge MJ: Prophylaxis of irinotecan-induced diarrhea with neomycin and potential role for UGT1A1*28 genotype screening: a double-blind, randomized, placebo-controlled study. Oncologist 2006,11(8):944-954.10.1634/theoncologist.11-8-944.
27. Michael M, Brittain M, Nagai J, Feld R, Hedley D, Oza A, Siu L, Moore MJ: Phase II study of activated charcoal to prevent irinotecan-induced diarrhea. J Clin Oncol 2004,22(21):4410-4417.10.1200/JCO.2004.11.125.
28. Sergio GC, Felix GM, Luis JV: Activated charcoal to prevent irinotecan-induced diarrhea in children. Pediatr Blood Cancer 2008,51(1):49-52.10.1002/pbc.21491.
29. Govindarajan R: Irinotecan/thalidomide in metastatic colorectal cancer. Oncology (Williston Park) 2002,16(4 Suppl 3):23-26.
30. Villalona-Calero M, Schaaf L, Phillips G, Otterson G, Panico K, Duan W, Kleiber B, Shah M, Young D, Wu WH, Kuhn J: Thalidomide and celecoxib as potential modulators of irinotecan's activity in cancer patients. Cancer Chemother Pharmacol 2007,59(1):23-33.
31. Wakelee H, Fisher GA: A phase I trial of irinotecan (CPT-11) with amifostine in patients with metastatic colorectal cancer. Investig New Drugs 2005,23(3):241-242.10.1007/s10637-005-6732-1.
32. Delioukina ML, Prager D, Parson M, Hecht JR, Rosen P, Rosen LS: Phase II trial of irinotecan in combination with amifostine in patients with advanced colorectal carcinoma. Cancer 2002,94(8):2174-2179.10.1002/cncr.10432.
33. Lam W, Bussom S, Guan F, Jiang Z, Zhang W, Gullen EA, Liu SH, Cheng YC: The four-herb Chinese medicine PHY906 reduces chemotherapy-induced gastrointestinal toxicity. Sci Transl Med 2010,2(45):45-59.
34. Farrell MP, Kummar S: Phase I/IIA randomized study of PHY906, a novel herbal agent, as a modulator of chemotherapy in patients with advanced colorectal cancer. Clin Colorectal Cancer 2003,2(4):253-256.10.3816/CCC.2003.n.007.
35. Kummar S, Copur MS, Rose M, Wadler S, Stephenson J, O'Rourke M, Brenckman W, Tilton R, Liu SH, Jiang Z, Su T, Cheng YC, Chu E: A phase I study of the chinese herbal medicine PHY906 as a modulator of irinotecan-based chemotherapy in patients with advanced colorectal cancer. Clin Colorectal Cancer 2011,10(2):85-96.10.1016/j.clcc.2011.03.003.
36. Yurkovetskiy L, Burrows M, Khan AA, Graham L, Volchkov P, Becker L, Antonopoulos D, Umesaki Y, Chervonsky AV: Gender bias in autoimmunity is influenced by microbiota. Immunity 2013,39(2):400-412.10.1016/j.immuni.2013.08.013.
37. David LA, Maurice CF, Carmody RN, Gootenberg DB, Button JE, Wolfe BE, Ling AV, Devlin AS, Varma Y, Fischbach MA, Biddinger SB, Dutton RJ, Turnbaugh PJ: Diet rapidly and reproducibly alters the human gut microbiome. Nature 2014,505(7484):559-563.
38. Hopkins MJ, Sharp R, Macfarlane GT: Age and disease related changes in intestinal bacterial populations assessed by cell culture, 16S rRNA abundance, and community cellular fatty acid profiles. Gut 2001,48(2):198-205.10.1136/gut.48.2.198.
39. Kabeerdoss J, Sankaran V, Pugazhendhi S, Ramakrishna BS: Clostridium leptum group bacteria abundance and diversity in the fecal microbiota of patients with inflammatory bowel disease: a case-control study in India. BMC Gastroenterol 2013, 13:20.10.1186/1471-230X-13-20.
40. Salzman NH, Hung K, Haribhai D, Chu H, Karlsson-Sjoberg J, Amir E, Teggatz P, Barman M, Hayward M, Eastwood D, Stoel M, Zhou Y, Sodergren E, Weinstock GM, Bevins CL, Williams CB, Bos NA: Enteric defensins are essential regulators of intestinal microbial ecology. Nat Immunol 2010,11(1):76-83.10.1038/ni.1825.
41. Ngan LT, Moon JK, Kim JH, Shibamoto T, Ahn YJ: Growth-inhibiting effects of Paeonia lactiflora root steam distillate constituents and structurally related compounds on human intestinal bacteria. World J Microbiol Biotechnol 2012,28(4):1575-1583.10.1007/s11274-011-0961-6.
42. Xing S, Wang M, Peng Y, Chen D, Li X: Simulated gastrointestinal tract metabolism and pharmacological activities of water extract of Scutellaria baicalensis roots. J Ethnopharmacol 2014,152(1):183-189.10.1016/j.jep.2013.12.056.
43. He J, Chen L, Heber D, Shi W, Lu QY: Antibacterial compounds from Glycyrrhiza uralensis. J Nat Prod 2006,69(1):121-124.10.1021/np058069d.
44. Daneshmand F, Zare-Zardini H, Tolueinia B, Hasani Z, Ghanbari T: Crude Extract from Ziziphus Jujuba Fruits, a Weapon against Pediatric Infectious Disease. Iran J Pediatr Hematol Oncol 2013,3(1):216-221.
45. Takasuna K, Hagiwara T, Hirohashi M, Kato M, Nomura M, Nagai E, Yokoi T, Kamataki T: Involvement of beta-glucuronidase in intestinal microflora in the intestinal toxicity of the antitumor camptothecin derivative irinotecan hydrochloride (CPT-11) in rats. Cancer Res 1996,56(16):3752-3757.
46. Zhang W, Saif MW, Dutschman GE, Li X, Lam W, Bussom S, Jiang Z, Ye M, Chu E, Cheng YC: Identification of chemicals and their metabolites from PHY906, a Chinese medicine formulation, in the plasma of a patient treated with irinotecan and PHY906 using liquid chromatography/tandem mass spectrometry (LC/MS/MS). J Chromatogr A 2010,1217(37):5785-5793.10.1016/j.chroma.2010.07.045.
47. Johansson ME, Phillipson M, Petersson J, Velcich A, Holm L, Hansson GC: The inner of the two Muc2 mucin-dependent mucus layers in colon is devoid of bacteria. Proc Natl Acad Sci U S A 2008,105(39):15064-15069.10.1073/pnas.0803124105.
48. Velcich A, Yang W, Heyer J, Fragale A, Nicholas C, Viani S, Kucherlapati R, Lipkin M, Yang K, Augenlicht L: Colorectal cancer in mice genetically deficient in the mucin Muc2. Science 2002,295(5560):1726-1729.10.1126/science.1069094.
49. Van der Sluis M, De Koning BA, De Bruijn AC, Velcich A, Meijerink JP, Van Goudoever JB, Buller HA, Dekker J, Van Seuningen I, Renes IB, Einerhand AW: Muc2-deficient mice spontaneously develop colitis, indicating that MUC2 is critical for colonic protection. Gastroenterology 2006,131(1):117-129.10.1053/j.gastro.2006.04.020.
50. Sato T, Vries RG, Snippert HJ, van de Wetering M, Barker N, Stange DE, van Es JH, Abo A, Kujala P, Peters PJ, Clevers H: Single Lgr5 stem cells build crypt-villus structures in vitro without a mesenchymal niche. Nature 2009,459(7244):262-265.10.1038/nature07935.
51. Barker N, van Es JH, Kuipers J, Kujala P, van den Born M, Cozijnsen M, Haegebarth A, Korving J, Begthel H, Peters PJ, Clevers H: Identification of stem cells in small intestine and colon by marker gene Lgr5. Nature 2007,449(7165):1003-1007.10.1038/nature06196.
52. van der Flier LG, van Gijn ME, Hatzis P, Kujala P, Haegebarth A, Stange DE, Begthel H, van den Born M, Guryev V, Oving I, van Es JH, Barker N, Peters PJ, van de Wetering M, Clevers H: Transcription factor achaete scute-like 2 controls intestinal stem cell fate. Cell 2009,136(5):903-912.10.1016/j.cell.2009.01.031.
53. Sangiorgi E, Capecchi MR: Bmi1 is expressed in vivo in intestinal stem cells. Nat Genet 2008,40(7):915-920.10.1038/ng.165.
54. Buchon N, Broderick NA, Chakrabarti S, Lemaitre B: Invasive and indigenous microbiota impact intestinal stem cell activity through multiple pathways in Drosophila. Genes Dev 2009,23(19):2333-2344.10.1101/gad.1827009.
55. Atreya I, Atreya R, Neurath MF: NF-kappaB in inflammatory bowel disease. J Intern Med 2008,263(6):591-596.10.1111/j.1365-2796.2008.01953.x.
56. Park YS: COX-2 inhibitors in inflammatory bowel disease: friends or foes? Korean J Gastroenterol 2007,50(6):350-355.
57. Kolios G, Valatas V, Ward SG: Nitric oxide in inflammatory bowel disease: a universal messenger in an unsolved puzzle. Immunology 2004,113(4):427-437.10.1111/j.1365-2567.2004.01984.x.